The Orange Book Transparency Act signed into law last year required the US Food and Drug Administration to solicit public comments on what patent information should be included in the Orange Book. The agency had already completed this task, so it reopened the docket for further input and is now evaluating possible revisions to the publication.
Last month, the FDA submitted a report to Congress summarizing the comments it received without specifying who made the comments or responding to them
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?